May 16, 2023 10:20 AM EDTUpdated May 17, 05:21 PM
News Briefing

BioX­cel touts healthy vol­un­teer da­ta for neu­ro ther­a­py; Io­n­is, Chi­nook part­ner on rare kid­ney dis­ease

Max Gelman

Senior Editor

Amber Tong

BioX­cel Ther­a­peu­tics re­port­ed some new healthy vol­un­teer da­ta that it’s tout­ing as pos­i­tive.

The biotech said in a press re­lease Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

Genen­tech vet launch­es ADC start­up with $20M

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times